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OBJECTIVES The purpose of this study was to evaluate the effect of chelation therapy with ethylenediamine
tetraacetic acid (EDTA) on endothelium-dependent vasomotor responses in patients with
documented coronary artery disease (CAD).
BACKGROUND Oxidative stress plays an important role in the dysfunction of endothelium and development
of atherosclerosis. Modification of cardiac risk factors and employment of antioxidants have
been shown to improve endothelial function. Ethylenediamine tetraacetic acid chelation
therapy is considered to be a complementary therapy for patients with CAD and is proposed
to have antioxidant properties.
METHODS A total of 47 patients enrolled in the Program to Assess Alternative Treatment Strategies to
Achieve Cardiac Health (PATCH) participated in this substudy and had complete data.
High-resolution ultrasound was used to assess endothelium-dependent brachial artery
flow-mediated vasodilation (FMD) in patients with CAD in a randomized, double-blind,
and placebo-controlled fashion. Patients were randomized to chelation therapy or placebo.
The primary end point was the absolute difference in FMD after the first and 33rd treatments
(6 months) of study groups compared with their baselines.
RESULTS At the baseline, the study population had mild impairment of FMD (7.2  3.4%). The first
chelation treatment did not change FMD as compared with placebo (chelation 6.5  3.5%
vs. placebo 7.4  2.9%; p value  0.371). The brachial artery studies at six months did not
demonstrate significant differences in FMD between study groups (placebo 7.3  3.4% vs.
chelation 7.3  3.2%; p value  0.961).
CONCLUSIONS Our results suggest that EDTA chelation therapy in combination with vitamins and minerals
does not provide additional benefits on abnormal vasomotor responses in patients with CAD
optimally treated with proven therapies for atherosclerotic risk factors. (J Am Coll Cardiol
2003;41:420–5) © 2003 by the American College of Cardiology Foundation
Chelation therapy or intravenous infusion of ethylenedia-
mine tetraacetic acid (EDTA) in combination with oral
vitamins and minerals is considered an “alternative” or
“complementary” therapy for patients with coronary artery
disease (CAD). It has been suggested that patients with
CAD might benefit from this complementary therapeutic
approach (1–4). However, definitive evidence that chelation
is beneficial has been lacking in randomized trials. Several
mechanisms for the potential beneficial effects of chelation
therapy in patients with atherosclerosis have been postu-
lated. Lamas and Ackermann (5) suggested that an antiox-
idant effect of EDTA, in combination with vitamins and
minerals, might be the most plausible.
Over the past decade, emerging data have demonstrated
that cardiovascular risk factors and oxidative stress play a
crucial role in abnormal vasomotor responses (6). Abnormal
vasomotor responses are probably one of the first events in
the atherosclerosis process and have been shown to be an
important cause of ischemia in patients with established
atherosclerosis (7). Furthermore, modification of cardiac
risk factors and employment of antioxidants have been
shown to improve endothelial function (8). On the basis of
previously proposed antioxidant, antihypertensive, and
cholesterol-lowering properties of chelation therapy (9), we
hypothesized that EDTA in combination with vitamins and
minerals may have a beneficial effect on endothelial function
in patients with established CAD.
The purpose of this study was to evaluate the effect of
chelation therapy with EDTA on endothelium-dependent
vasomotor responses in patients with documented CAD in
a randomized, double-blind, and placebo-controlled fash-
ion.
METHODS
Study subjects. A total of 53 patients enrolled in the
Program to Assess Alternative Treatment Strategies to
Achieve Cardiac Health (PATCH) study participated in
this substudy. The main PATCH study has been previously
reported (10). Briefly, patients 21 years old with CAD
proven by coronary angiography or a documented myocar-
dial infarction and stable angina on optimal medical therapy
were studied. To qualify for randomization, patients were
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required to have a treadmill test using a gradual ramping
protocol and demonstrating 1 mm horizontal or
downsloping ST depression from the isoelectric line 80 ms
after the J point. The study required detection of ST
depression between 2 and 14 min from the onset of exercise.
Patients were excluded for the following reasons: planned
revascularization, previous chelation therapy, evidence of
heart failure, inability to walk on the treadmill, resting
electrocardiogram changes that would interfere with isch-
emic assessment, abnormal renal or liver function, or un-
treated lipid abnormality at the time of randomization.
Study protocol. RANDOMIZATION AND TREATMENT.
Written informed consent was obtained from all partici-
pants. The Conjoint Ethics Committee of the University of
Calgary and the Calgary Regional Health Authority ap-
proved this study and its consent form. All clinical events
were reported to an independent Safety Monitoring Com-
mittee. The present study was a double-blind, randomized,
and placebo-controlled trial. Patients were randomized in
blocks of 10 using S-plus version 3.4 (Statistical Science
Inc., Seattle, Washington). The Foothills Medical Center
Pharmacy assigned the randomized therapy and prepared
solutions for blinded administration of infusions. The 500
ml infusion solution of 5% dextrose in water for the active
treatment containing disodium EDTA (Endrate, Abbott
Laboratories) was weight adjusted (40 mg/kg), with a
maximum total dose for each treatment of 3 g. Each
treatment solution also contained 750 mg of magnesium
sulfate, 5 g of ascorbic acid (Mega C), and 5 g sodium
bicarbonate (titrated to physiologic pH) in the D5W.
Lidocaine (Xylocaine ) 80 mg was added to relieve pain at
the administration site and mask taste. In the placebo
infusion solution, the EDTA was replaced by 20 ml of 0.9%
sodium chloride. The infusion solutions were indistinguish-
able by color, taste, and labeling. All infusion solutions were
prepared following manufacturers’ instructions and were
administered immediately after mixing. The infusion solu-
tion was administered over 3 h to minimize the potential
unblinding effect of infusion-related side effects. All patients
received treatments twice weekly for 15 weeks and once per
month for an additional three months, for a total of 33
treatments. In accordance with the American College of
Advancement in Medicine protocol, patients in both groups
took oral multivitamin therapy (FLW, Douglas Labs, Pitts-
burgh, Pennsylvania), two tablets three times daily as
tolerated, except on treatment days. The components of
FLW were as follows: vitamin A 4,000 IU, vitamin E 65
IU, vitamin C 400 mg, vitamin B1 20 mg, vitamin B2 5 mg,
vitamin B6 15 mg, vitamin B12 25 g, niacin 5 mg,
niacinamide 5 mg, pantothenic acid 50 mg, folic acid 0.04
mg, biotin 10 g, choline 72.5 mg, inositol 5 mg, methio-
nine 24 mg, magnesium 40 mg, potassium 40 mg, manga-
nese 0.5 mg, zinc 3 mg, chromium 20 g, and selenium 25
g. All patients were seen at the University of Calgary
Cardiovascular Risk Reduction Clinic and had treatment of
their risk profile optimized.
BRACHIAL ENDOTHELIAL FUNCTION STUDIES. A recently
described technique employing high-resolution ultrasound
to measure brachial artery diameter was used to study the
vasodilator responses induced by reactive hyperemia after 5
min of upper arm occlusion (11). Assessment of brachial
artery endothelial function was performed at baseline, after
the first chelation therapy (acute), and at the end of study
(after the completion of 33 chelation treatments) by a
previously validated technique (12,13). Patients underwent
each of three brachial artery ultrasound studies after an
overnight fast (12 h), and all vasoactive medications, includ-
ing angiotensin-converting enzyme (ACE) inhibitors, beta-
blockers, calcium-channel blockers, long-acting nitrites, and
statins were stopped for 24 h. Studies were performed in a
quiet clinical laboratory with the temperature maintained at
21 to 23°C. A 7.5 MHz linear phase-arrayed ultrasound
transducer attached to a Hewlett-Packard 5500 ultrasound
machine was used. Pulsed-wave Doppler was used to record
brachial artery velocity for each of the interventions.
Data analysis. BRACHIAL ARTERY ANALYSIS. Brachial ar-
tery analysis was performed at a core laboratory at the
University of Calgary by a single technician blind to the
study group assignment or study sequence. Three sequential
systolic frames (taken at the end of the T-wave on the
electrocardiogram) were digitized via an analog-to-digital
converting board. A software algorithm automatically cal-
culates the average diameter (100 points) over the operator-
selected segment. Flow-mediated vasodilation (FMD) was
calculated from the diameters as (reactive hyperemia 
baseline)/baseline  100%. The intra- and inter-observer
variability in our laboratory is 1%. Systolic frames were used
as previously validated (13). In 20 studies selected randomly,
measurements were made at both end-diastole and systole,
and the FMD was exactly the same. Brachial artery flow was
calculated as the product of velocity and cross-sectional
arterial area.
STATISTICS. Data are expressed as mean  SD for contin-
uous variables and as counts and percentage for discrete
variables. Statistical analyses were conducted with a com-
mercially available software package (SPSS version 10.0;
SPSS Inc, Chicago, Illinois). The sample size was deter-
mined to detect a clinically important absolute improvement
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CAD  coronary artery disease
EDTA  ethylenediamine tetraacetic acid
eNOS  endothelial nitric oxide synthase
FMD  flow-mediated vasodilation
NO  nitric oxide
NTG  nitroglycerin
PATCH  Program to Assess Alternative Treatment
Strategies to Achieve Cardiac Health
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in FMD of 3% (with a SD of 3% to 4%) in the chelation
group when compared with placebo. This assumes an alpha
of 0.05 and beta 0.2. Categorical variables were analyzed
with the Mann-Whitney U-test. Continuous variables were
examined with paired and unpaired t tests, as appropriate.
All reported significance levels are two-sided.
RESULTS
Patient characteristics. A total of 53 patients agreed and
consented to participate in the study between January 1996
and January 2000. Of the 53 patients, 47 completed
treatment and final brachial artery ultrasound study. Four
placebo patients were unable to finish the treatment phase
because of: 1) cancer of the hip; 2) hospitalization with
pneumothorax in the setting of previous asbestosis and
chronic obstructive pulmonary disease; 3) unstable angina
followed by angioplasty and coronary artery bypass graft
surgery; and 4) coronary artery bypass graft surgery that had
been planned as an elective procedure by the primary
cardiologist after randomization without the knowledge of
the investigators. Two EDTA patients were unable to
complete the study: one because of a serum creatinine level
increase above preset study limit (175 mol/l) and the other
because of hospitalization for unstable angina followed by
withdrawal of consent. There was no difference in the
demographics of these patients and those who completed
the study. Data presented in this report are from the 47
patients with complete information. The baseline charac-
teristics of the 47 randomized patients are shown in Table 1.
There were no important differences at baseline between the
two groups. The mean age of the study population was 68
 9 years, with 85% men. Risk factors were as follows:
hypercholesterolemia 80%, hypertension 43%, and diabetes
mellitus 10%. All patients had treatment of their risk profile
optimized. Among all 47 patients, 95% were treated with
aspirin, 80% with lipid-lowering therapies, 70% with beta-
blockers, 34% with ACE inhibitors, and 30% with long-
acting nitrates. The use of medication was comparable
between the randomization groups. During the course of
the study, there was no statistically significant difference in
lipid profile or in blood pressure between the groups.
Treatment effect on brachial artery characteristics. Flow-
mediated vasodilation was inversely related to baseline
brachial artery diameter in this study (baseline 4.1  0.7
mm vs. FMD diameter 4.3  0.8 mm; p value 0.001) and
in other studies (13–15). The baseline brachial artery
diameter was the same for both study groups, and the study
medications had no significant effect on baseline brachial
diameter after six months of treatment. Upper arm occlu-
sion resulted in an increase in forearm blood flow of
approximately 450%, which was the same at baseline for
both groups and was not affected by drug treatment.
Treatment effect on FMD. At the baseline, the study
population had FMD of 7.2  3.4% and nitroglycerin
(NTG)-mediated dilation of 13.2  5.7%. These values are
similar to what we have reported previously in patients with
CAD (14) and less than those of normal controls in our lab
(16). Baseline FMD and NTG-mediated vasodilations were
similar in both groups (Table 2). Short-term treatment with
EDTA in combination with vitamins and minerals did not
changed FMD and NTG-mediated vasodilation (Table 2).
The brachial artery studies at six months, after the comple-
tion of 33 treatments, did not demonstrate significant
differences in FMD between placebo and chelation therapy
groups (placebo 7.3  3.4% vs. chelation 7.3  3.2%; p
value  0.961) (Table 2). There was no significant effect of
chelation therapy on NTG-induced vasodilation (placebo
12.4  6.4% vs. chelation group 15.3  7.1%; p value 
0.148) (Table 2). Furthermore, we did not observe any
statistically significant changes within either study group
over time (Fig. 1).
Table 1. Baseline Demographics
Placebo
(n  23)
Chelation
(n  24) p Value
Age 64  9 64  9 0.939*
Male 19 (83%) 21 (88%) 0.641
Female 4 (17%) 3 (13%) 0.641
Postmenopausal 4 (17%) 3 (13%) 0.641
Diabetes mellitus 1 (4%) 4 (17%) 0.176
Hypertension 11 (48%) 9 (38%) 0.479
Smoker 1 (4%) 1 (4%) 0.976
CHF 1 (4%) 1 (4%) 0.976
PVD 3 (13%) 2 (8%) 0.605
Lipids (mmol/l)
Total cholesterol 5.0  1.1 4.9  0.8 0.760*
LDL-C 3.0  0.7 2.9  0.7 0.639*
HDL-C 1.1  0.2 1.1  0.3 0.975*
Triglycerides 2.0  1.1 2.8  3.9 0.356*
CHF  history of congestive heart failure; HDL-C  high-density lipoprotein
cholesterol; LDL-C  low-density lipoprotein cholesterol; p value  chelation
therapy versus placebo group; unpaired t test and Mann-Whitney U-test (*); PVD 
peripheral vascular disease
Table 2. Brachial Artery Parameters
Placebo Chelation p Value
Baseline
Baseline diameter (mm) 4.1  0.7 4.0  0.8 0.974
FMD (%) 7.6  3.4 6.7  3.5 0.355
NTG (%) 12.8  5.0 13.5  6.3 0.664
Short-term
Baseline diameter (mm) 4.1  0.8 4.1  0.7 0.769
FMD (%) 7.4  2.9 6.5  3.5 0.371
NTG (%) 12.0  4.9 12.8  4.1 0.516
6-month
Baseline diameter (mm) 4.1  0.5 4.0  0.8 0.625
FMD (%) 7.3  3.4 7.3  3.2 0.961
NTG (%) 12.4  6.4 15.3  7.1 0.148
baseline  measurement performed before the treatment, after the first chelation
therapy (short-term) and after the completion of 33 chelation treatments; data
presented in millimeters as mean SD for baseline diameter and in % SD increase
from baseline diameter for FMD and NTG; FMD  flow-mediated vasodilation;
NTG  nitroglycerin-mediated vasodilation; p value  chelation therapy versus
placebo group; unpaired t test.
422 Anderson et al. JACC Vol. 41, No. 3, 2003
Effect of EDTA Chelation on Endothelial Function February 5, 2003:420–5
DISCUSSION
This randomized, double-blind, and placebo-controlled
study demonstrates that short- and long-term treatment (33
infusions) with EDTA in combination with vitamins and
minerals did not improve impaired endothelium-dependent
FMD in the brachial artery circulation of patients with
established CAD and optimized treatment of risk profile.
There is ample evidence that the endothelium plays an
important role in maintaining vascular integrity through the
release of a variety of paracrine and autocrine factors,
including nitric oxide (NO). In health, NO causes vasodi-
lation, inhibits platelet aggregation and adhesion, and in-
hibits smooth muscle cell proliferation and white cell
adhesion (17). Endothelial dysfunction has been observed in
patients with established CAD or coronary risk factors, both
in coronary and peripheral circulation (12,18). Oxygen free
radicals, generated by a number of pathways in the body,
play an important role in the dysfunction of endothelium
and development of atherosclerosis (19). Modification of
cardiac risk factors and employment of antioxidants have
been shown to improve endothelial function (8).
Chelation therapy is considered to be complementary
therapy for patients with CAD. In fact, the beneficial effect
of EDTA therapy in this setting remains unproven (5,10).
Originally, liberation of plaque calcium with a subsequent
favorable change in the properties of the plaque (20–23) was
thought to be the underlying mechanism of action. Later,
EDTA was proposed to lower low-density lipoprotein and
very-low-density lipoprotein levels and iron stores, inhibit
platelet aggregation, relax vascular tone, and “scavenge” free
Figure 1. Changes in vasomotor responses in study groups over time. (A) placebo group; (B) chelation therapy group; *p value  0.05 (baseline vs. acute
vs. 6 months) paired t test. FMD  flow-mediated vasodilation; NTG  nitroglycerin.
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radicals (5,20–29). Ethylenediamine tetraacetic acid reduces
iron and copper levels from cell membrane. Both these
metals are important catalysts in the peroxidation of unsat-
urated fatty acids and the oxidation of low-density lipopro-
tein, which generate free radicals with subsequent disrup-
tion of membrane architecture, promoting cellular injury
and progression of atherosclerosis (30). The beneficial effect
of iron chelation on endothelial function has been previously
demonstrated. Deferoxamine, an iron chelator, improved
NO-mediated, endothelium-dependent vasodilation in pa-
tients with CAD (31) and in diabetics with angiographically
normal coronary arteries (32). On the other hand, in a
non-randomized and non-blinded study (33), EDTA alone
did not significantly improve either endothelium or NO-
dependent vasodilation in patients with CAD after 10
chelation infusions over 60 days. However, EDTA in
combination with predominantly B vitamins improved va-
somotor responses and was associated with a significant
reduction in homocysteine levels. The patients in our study
had documented CAD and impaired endothelial function in
peripheral circulation at baseline. An improvement in ab-
normal vasomotor responses has not been observed in
patients randomized to EDTA therapy compared with
patients randomized to placebo, either in the short term or
at six months. Furthermore, we have not demonstrated any
statistically significant changes in FMD or NTG-mediated
vasodilation within the study groups over time. One possi-
ble explanation might be that EDTA, unlike deferoxamine,
is too small to bind entire iron ions and it creates a seventh
coordination site (34). As a result, iron remains in its
catalytically active form, and EDTA-iron complex can
catalyze the formation of the hydroxyl radical in a superox-
ide generating system (35).
In our study, “placebo treatment” contained a high dose
of intravenous vitamin C and multivitamin oral supplemen-
tation. Therefore, we cannot exclude a beneficial effect of
treatment with vitamins and minerals alone. Vitamin C is a
water-soluble antioxidant that inhibits lipid peroxidation in
vitro (36) and in vivo (37) by directly scavenging aqueous
free radicals, by reducing the chain-carrying alpha-
tocopheroxyl radical, and by stabilization of tetrahydrobiop-
terin, which prevents uncoupling of eNOS (38,39). In
clinical studies, vitamin C has been shown to reverse
impaired endothelial function in patients with established
CAD (40,41). However, long-term vitamin C supplemen-
tation did not show a consistent beneficial effect on the
endothelial function of treated patients (42). The reason
why our patient population, either in the EDTA or placebo
group, did not respond to vitamin C treatment is not clear.
All our patients were aggressively treated for atherosclerotic
risk factors. The majority of our study population was
treated with lipid-lowering therapy and 34% of patients
used ACE inhibitors. Lipid-lowering therapies and ACE
inhibition have been shown to augment endothelial NO
synthesis, to inhibit endothelial superoxide anion in animal
studies (43–46), and to have beneficial effects on abnormal
vasomotor responses in humans (47–50). Therefore, it can
be speculated that free radical production was suppressed
below the level at which free radical scavengers used in the
presented study (EDTA and vitamin C) could demonstrate
their beneficial effect on vasomotor responses. It was a
limitation of our study that we did not have a measure of
oxidative stress or vitamin C levels.
In conclusion, our results suggest that chelation therapy
with EDTA in combination with vitamins and minerals
does not provide any additional benefit on abnormal vaso-
motor responses in patients with CAD optimally treated for
atherosclerotic risk factors with proven therapies.
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